Business
Novo Nordisk Shares Plunge 20% After Disappointing CagriSema Trial Results
Novo Nordisk experienced its sharpest one-day decline in history on Friday as shares of the Danish pharmaceutical giant plummeted 20% following underwhelming trial results for its new obesity drug, CagriSema. The drop wiped out €90 billion in market valuation, significantly impacting the year-to-date performance of Europe’s largest company, which is now down 16% in 2024.
CagriSema Misses Expectations
The phase 3 trial for CagriSema revealed a weight loss of 22.7% over 68 weeks, below the projected 25% benchmark. The figure fell further to 20.4% among patients who did not strictly adhere to the treatment regimen. The results raised concerns about Novo Nordisk’s competitiveness in the rapidly growing obesity and diabetes drug market.
Eli Lilly, Novo Nordisk’s primary U.S.-based rival, reported a 24% weight loss in September with its latest drug, retatrutide. Eli Lilly’s stock surged 10% before closing 1.35% higher on Friday and has gained 32% this year, a stark contrast to Novo Nordisk’s performance.
Adding to the disappointment, only 57% of CagriSema trial participants reached the highest dose, compared to 83% for cagrilintide and 70% for semaglutide in previous studies. Concerns about the drug’s side effects and market positioning have tempered investor expectations.
“Based on insights from the REDEFINE 1 trial, we will explore additional weight loss potential for CagriSema,” said Martin Holst Lange, Novo Nordisk’s executive vice president for Development. Results from a second phase 3 trial, REDEFINE 2, are expected in the first half of 2025.
Heightened Competition in the Weight-Loss Market
The global market for weight-loss and diabetes drugs, including GLP-1 treatments, is projected to grow to between $150 billion and $200 billion by 2030. Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic accounted for 61% of the company’s sales in the first nine months of 2024.
Eli Lilly has emerged as a formidable competitor with its weight-loss drugs Zepbound and Mounjaro. The U.S.-based company, valued at $691 billion (€662 billion), has positioned itself as a market leader, with analysts expecting the two firms to evenly split the weight-loss market by the end of 2024.
Future Challenges for Novo Nordisk
Novo Nordisk faces mounting pressure to expedite next-generation drug development as the patent for Wegovy is set to expire in the early 2030s. The disappointing results for CagriSema have raised doubts about the company’s ability to sustain its dominance in the sector.
The U.S. remains Novo Nordisk’s largest market, accounting for 35% of its diabetes drug sales as of August 2024. While the company’s valuation peaked in June, Friday’s market reaction underscores the challenges it faces in retaining its competitive edge in a rapidly evolving industry.
Business
Global Markets Rise as US–Iran Talks Ease Sentiment, but Oil and Geopolitical Risks Persist
Global financial markets advanced on Friday as investors reacted cautiously to signs of progress in US–Iran negotiations, though ongoing disruption to shipping through the Strait of Hormuz and elevated oil prices kept risk sentiment fragile.
European equities opened higher across the board. The DAX gained 0.64%, supported by a 3.61% rise in Deutsche Post AG shares. France’s CAC 40 climbed 0.65%, led by a 3.43% jump in STMicroelectronics. In London, the FTSE 100 rose 0.38%, with gains in financial stocks including 3i Group, while the Euro Stoxx 50 added 0.88%.
Currency markets were relatively steady, with the euro trading at $1.161 and the British pound at $1.342 in early European trading. Sentiment was also lifted by better-than-expected economic data from Germany, where first-quarter growth came in at 0.4% year on year and consumer confidence improved heading into June, offering cautious optimism for Europe’s largest economy.
Asian markets followed the upward trend. Japan’s Nikkei 225 surged 2.7% to 63,339 after data showed inflation easing to a four-year low of 1.4% in April. Taiwan’s Taiex rose 2.2%, while Hong Kong’s Hang Seng and China’s Shanghai Composite each gained 0.9%. South Korea, Australia, and India also posted modest increases, reflecting broad regional strength.
Wall Street had earlier closed slightly higher. The S&P 500 added 0.2%, the Dow Jones rose 0.6%, and the Nasdaq edged up 0.1%. However, technology stocks showed mixed signals, with Nvidia falling 1.8% despite strong quarterly results, as investors weighed valuations against broader market uncertainty.
Oil markets remained the key source of volatility. Brent crude climbed 2.3% to $104.97 a barrel, while US West Texas Intermediate rose 1.8% to $98.10. Prices remain significantly above pre-conflict levels, driven by continued disruption in the Strait of Hormuz, through which roughly a quarter of global seaborne oil flows pass.
Shipping through the strategic waterway remains constrained, with limited signs of recovery as diplomatic negotiations continue without resolution. Analysts say markets are highly sensitive to developments in talks between Washington and Tehran, with ING commodities strategists noting that optimism exists but uncertainty dominates trading conditions.
Geopolitical tensions also weighed on policy discussions in Washington, where a planned congressional vote on war powers legislation was postponed amid insufficient support.
In bond markets, US Treasury yields eased slightly to 4.57% after earlier spikes driven by inflation concerns linked to energy prices. The movement reflected ongoing caution among investors balancing growth expectations with persistent geopolitical risk.
Corporate earnings added a bright spot in Asia, where Lenovo Group surged more than 20% after reporting stronger-than-expected quarterly revenue of $21.6 billion, driven by robust performance in its PC and smart devices division.
Business
Goldman Sachs tapped to lead SpaceX IPO as Musk eyes record-breaking market debut
Business
Greek Stocks Stage Remarkable Comeback After Years of Financial Turmoil
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
